Elon Musk has confirmed that American automaker Tesla is currently working on a third version of the COVID-19 vaccine printer for the German company CureVac, and believes it will be "an important product for the whole world."
Musk's idea is that once CureVac develops a vaccine, the company will need a way to distribute it massively around the world.
Earlier this year, Musk announced that Tesla has become a manufacturing partner with biotech firm CureVac, which is working on an RNA-based COVID-19 vaccine.
Tesla CEO announced that the company will “build micro RNA factories for the CureVac.”
Tesla will receive compensation for building vaccine micro-factories if the project is successful, but Musk says investors shouldn't take that into account.
Tesla has jointly filed a patent with CureVac for a revolutionary "RNA bioreactor."
The automaker will build an automated RNA printing system and deploy it around the world.
CureVac has found a way to synthesize an RNA molecule and enable it to fight certain diseases in the body.
The company has been working on treatments for other strains of influenza, but has focused on COVID-19 during the pandemic, and they recently moved into a second phase of clinical trials.